

### **Teaching Experience:**

1991-1998 Ben Gurion University- School Of Medicine  
Role: Instructor in Psychiatry

### **Departmental and Invited Lectures:**

1981 Transmembrane Transport System; A Review  
1997 Bulimia Nervosa  
1999 Emergency Psychiatry  
2001 Stigma in Psychiatry  
2013 Ft. Worth, TX Alternative therapies to depression treatment, Keynote Spreaker at "2<sup>nd</sup> Annual South Plaines Suicide Prevention Coalition Regional Symposiom"  
2015 "How and why to set up a Ketamine treatment clinic with a psychiatrist and Anesthesiologist" (Workshop) – 10<sup>th</sup> International Congress of the International Neuropsychiatric Association- Jerusalem, Israel

### **Research Programs:**

1983 The secondary effects or two Imidazole Derivates: An animal study (Advisor: Dr. Nechifor, Dept. of Pharmacology, "GR T POPA" Medical School- Iasi, Romania)  
1987 Non paroxysmal AV Junctional Tachycardia (Advisor: Dr.C Marcu, Dept of Cardiology, "GR. T POPA" Medical School – Iasi, Romania)  
1993-1994 A double blind multicenter study on Seroquel (Co-Investigator; Ben Gurion University- Beer Sheva, Israel)  
1995 Efficacy and Safety of Olanzapine in the treatment of schizophrenic patients not responsive to Risperdone (Co-Investigator; Ben Gurion University- Beer Sheva, Israel)  
1995 A randomized open label multicenter study comparing the safety and tolerance of I.M Ziprasidone Hydrochloride or Oral Haloperidol in patients with acute non-organic psychosis (Co-Investigator; Ben Gurion University- Beer Sheva, Israel)  
2000 Assesing suicide risk by computerized suicide risk scale- Version 2.0; Cross- Validation among Psychiatric Inpatients- (Research approved February 2000) (Co-Investigator; Shaar Menashe Mental Health Center- Israel)  
2000 Therapeutic Efficacy of ECT and Olanzapine vs Clozapine in treatment resistant schizophrenia, an open label trial (Principal Investigator; Shaar Menashe Mental Health Center- Israel)

N.Grisaru, **D.Ghelber**, E. Witztum: An Integrative Strategic Treatment with Narcoanalysis in a case of Post-Traumatic Conversive Disorder, Sihot- Israel J of Psychotherapy, 1999, 8 (2):135-142

Modai, I.; Hirschmann, S.; Hadjez, J.; Bernat, C.; **D.Ghelber**.; Ratner, Y .; Rivkin, O.; Kurs, R.; Ponizovsky, A.; Ritsner, M; Clinical evaluation of prior suicide attempts and suicide risk in psychiatric inpatients. Crisis, 2002; 23;47-54

**D.Ghelber**, Y. Levin and R.H Belmaker Effect of Inositol on Bulimia Nervosa and Binge Eating Dis, 2001, 29: 345-348

**D.Ghelber**, R.H Belmaker Tardive Dyskinesia with Quetiapine, Am J Psychiatry, Publication 1999, 156, P :5

**D.Ghleber** Y. Levin and R.H Belmaker Inositol Treatment of Bulimia Nervosa. A Double Blind Cross Over Study. (Poster), 12<sup>th</sup> ECNP 1999, London, UK

**D.Ghelber**, H. Einat and R.H Belmaker Chronic Epi-inositol is Anxiolytic in The Plus Maze Model in Rats (poster), 11<sup>th</sup> ECNP congress, 1988- Paris, France

**D.Ghelber**, Y. Levin and R.H Belmaker Inositol Treatment of Bulimia Nervosa. A Double Blind Cross over Study. Preliminary results. (poster) 10<sup>th</sup> ECNP, 1997 – Vienna, Austria

**D.Ghelber**, N.Grisaru and E. Witztum, Narcohypnotic Therapy of Hysterical Quadraplegia with Aphonia, 7<sup>th</sup> European Congress if Hypnosis, 1996- Budapest, Hungary

Y.Bersudski, Y.Vinnitsky, **D.Ghleber**, O. Hoffman, Z.Kaplan and R.H Belmaker, Mechanism of Lithium Lethality in Rats J. Psychiat Res, 1993, 27 . (4), P :415-422

**D. Ghelber**, K. Khanal : Brainsway™ dTMS and Brainsway™ dTMS with Ketamine Infusions in Treatment-Resistant Depression; Real Life Results  
Clinical TMS society annual meeting, May 11-13 2018, New York, NY, USA

**Selected Clinical Trial Experience:**

A Randomized, Double-Blind, Placebo Controlled Study of XXXX for the Treatment of Moderate to Severe Tardive Dyskinesia (Phase II)

An Open-Label, Long-Term Safety Study of XXXX for the Treatment of Moderate to Severe Tardive Dyskinesia (Phase III)

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of XXXX for the Treatment of Moderate to Severe Tardive Dyskinesia (Phase III)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of XXXX for the Treatment of Tardive Dyskinesia

A Phase 3, Open-Label, Safety and Tolerability Study of XXXX for the Treatment of Tardive Dyskinesia.

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX in Adult Subjects with Tourette Syndrome (Phase II)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX in Pediatric Subjects with Tourette Syndrome (Phase II)

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXXX as Adjunctive Therapy in Major Depressive Disorder (Phase III)

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXXX as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder (Phase III)

An Open-label, Long-term Safety Study of XXXX as Adjunctive Therapy in Patients with Major Depressive Disorder (Phase III)

Interventional, randomized, double-blind, active controlled, fixed-dose study of XXXX in patients with Treatment-resistant Schizophrenia